Cynthia X. Ma, MD, PhD, on Metastatic Breast Cancer: Early Results on Copanlisib, Fulvestrant, and Abemaciclib
2023 SABCS
Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, discusses phase I findings showing the safety and tolerability of copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer. Preliminary antitumor activity, which was observed, will be further examined in the phase II trial (ClinicalTrials.gov identifier NCT03939897) (Abstract PS17-06).
The ASCO Post Staff
Seema Khan, MD, of Northwestern University and the Robert H. Lurie Comprehensive Cancer Center, discusses the 5-year clinical outcomes of ECOG-ACRIN 4112, a prospective trial that supports the omission of radiotherapy after surgery in patients with ductal carcinoma in situ who have a low DCIS score and its use in patients with intermediate/high DCIS scores (Abstract GS03-01).
The ASCO Post Staff
Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the NATALEE trial, which continued to demonstrate improved invasive disease–free survival with ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) over a NSAI alone in patients with hormone receptor–positive, HER2-negative early breast cancer (Abstract GS03-03).
The ASCO Post Staff
Peter Schmid, MD, PhD, of Queen Mary University of London and Barts Cancer Institute, discusses phase III findings from KEYNOTE-522 showing that neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab continues to show a clinically meaningful improvement in event-free survival compared with neoadjuvant chemotherapy alone in patients with early-stage triple-negative breast cancer (TNBC) (Abstract LBO1-01).
The ASCO Post Staff
Senthil Damodaran, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses final results from the FOENIX-MBC2 study of the efficacy and safety of futibatinib in patients with locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring high-level FGFR1 gene amplification. Futibatinib plus fulvestrant showed antitumor activity in those whose disease had progressed on prior CDK4/6 inhibitors (Abstract RF01-04).
The ASCO Post Staff
Sherene Loi, MD, PhD, of Australia’s Peter McCallum Cancer Centre, discusses recent data showing that for patients with stage I/II triple-negative breast cancer, 12 weeks of a neoadjuvant nonanthracycline chemotherapy regimen with nivolumab may be efficacious with either concurrent or lead-in nivolumab. Those with immune-enriched tumors had high pathologic complete response rates, identifying a subpopulation for whom a 12-week anthracycline-free chemotherapy regimen with nivolumab may be appropriate (Abstract LBO1-03).
